Actavis has launched a portfolio of generic specialty injectable medications to be marketed to hospitals in the U.S. Actavis will begin marketing approximately 20 injectable products across a number of therapeutic areas in the U.S., including generic versions of oncology drugs Gemzar, Taxotere, Campostar and Zometa. Actavis also has a specialty injectable pipeline, with approximately 20 new filings under FDA review and more than 50 additional projects in development.
 
Many of the generic specialty injectable products were previously marketed in the U.S. by Sagent Pharmaceuticals under a manufacturing and supply agreement dating back to 2010. Actavis regained U.S. marketing rights following the expiration of the Sagent agreement in December 2014.
 
“Over the last several years, we have been steadily growing our generic specialty injectable business around the world, marketing products in more than 50 countries,” said Brent Saunders, chief executive officer and president of Actavis. “With the addition of this diverse portfolio of injectable products to our U.S. portfolio, we will create a leading specialty injectable business within Actavis and immediately become a strong competitor in this important, high-value space. In addition, we will continue to invest in the development of our industry-leading generic injectable pipeline as part of our strategy to drive growth through complex, high-barrier-to-entry products.”